Satsuma Pharmaceuticals, Inc.

Report readout of the second STS101 Phase 3 efficacy trial

Deadline passed; outcome being checked

Announced: 1 Mar 2021
Due: 31 Dec 2022
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“Readout of second STS101 Ph3 efficacy trial in 2H 2022”

SourceSatsuma Pharmaceuticals, Inc. Form 8-K press release, 2021-03-01
FilingSEC filing index
Deadline as statedin 2H 2022
Deadline used31 Dec 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-C692830-024825
Cite as https://keptindex.org/c/KI-C-2021-C692830-024825/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: Readout of second STS101 Phase 3 efficacy trial
In the company’s control: Medium
Specificity: High

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Satsuma Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C692830-024825 · Corrections policy